FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991498260> ?p ?o ?g. }

• W1991498260 endingPage "1304" @default.
• W1991498260 startingPage "1297" @default.
• W1991498260 abstract "Small studies suggest peanut oral immunotherapy (OIT) might be effective in the treatment of peanut allergy. We aimed to establish the efficacy of OIT for the desensitisation of children with allergy to peanuts.We did a randomised controlled crossover trial to compare the efficacy of active OIT (using characterised peanut flour; protein doses of 2-800 mg/day) with control (peanut avoidance, the present standard of care) at the NIHR/Wellcome Trust Cambridge Clinical Research Facility (Cambridge, UK). Randomisation (1:1) was by use of an audited online system; group allocation was not masked. Eligible participants were aged 7-16 years with an immediate hypersensitivity reaction after peanut ingestion, positive skin prick test to peanuts, and positive by double-blind placebo-controlled food challenge (DBPCFC). We excluded participants if they had a major chronic illness, if the care provider or a present household member had suspected or diagnosed allergy to peanuts, or if there was an unwillingness or inability to comply with study procedures. Our primary outcome was desensitisation, defined as negative peanut challenge (1400 mg protein in DBPCFC) at 6 months (first phase). Control participants underwent OIT during the second phase, with subsequent DBPCFC. Immunological parameters and disease-specific quality-of-life scores were measured. Analysis was by intention to treat. Fisher's exact test was used to compare the proportion of those with desensitisation to peanut after 6 months between the active and control group at the end of the first phase. This trial is registered with Current Controlled Trials, number ISRCTN62416244.The primary outcome, desensitisation, was recorded for 62% (24 of 39 participants; 95% CI 45-78) in the active group and none of the control group after the first phase (0 of 46; 95% CI 0-9; p<0·001). 84% (95% CI 70-93) of the active group tolerated daily ingestion of 800 mg protein (equivalent to roughly five peanuts). Median increase in peanut threshold after OIT was 1345 mg (range 45-1400; p<0·001) or 25·5 times (range 1·82-280; p<0·001). After the second phase, 54% (95% CI 35-72) tolerated 1400 mg challenge (equivalent to roughly ten peanuts) and 91% (79-98) tolerated daily ingestion of 800 mg protein. Quality-of-life scores improved (decreased) after OIT (median change -1·61; p<0·001). Side-effects were mild in most participants. Gastrointestinal symptoms were, collectively, most common (31 participants with nausea, 31 with vomiting, and one with diarrhoea), then oral pruritus after 6·3% of doses (76 participants) and wheeze after 0·41% of doses (21 participants). Intramuscular adrenaline was used after 0·01% of doses (one participant).OIT successfully induced desensitisation in most children within the study population with peanut allergy of any severity, with a clinically meaningful increase in peanut threshold. Quality of life improved after intervention and there was a good safety profile. Immunological changes corresponded with clinical desensitisation. Further studies in wider populations are recommended; peanut OIT should not be done in non-specialist settings, but it is effective and well tolerated in the studied age group.MRC-NIHR partnership." @default.
• W1991498260 created "2016-06-24" @default.
• W1991498260 creator A5005241960 @default.
• W1991498260 creator A5010334043 @default.
• W1991498260 creator A5018741279 @default.
• W1991498260 creator A5018814169 @default.
• W1991498260 creator A5034582010 @default.
• W1991498260 creator A5042582706 @default.
• W1991498260 creator A5051267341 @default.
• W1991498260 creator A5059565310 @default.
• W1991498260 creator A5084298635 @default.
• W1991498260 creator A5091157379 @default.
• W1991498260 date "2014-04-01" @default.
• W1991498260 modified "2023-10-07" @default.
• W1991498260 title "Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial" @default.
• W1991498260 cites W1525297992 @default.
• W1991498260 cites W1531304022 @default.
• W1991498260 cites W1741971985 @default.
• W1991498260 cites W1989102837 @default.
• W1991498260 cites W1989665816 @default.
• W1991498260 cites W1994095603 @default.
• W1991498260 cites W2006208839 @default.
• W1991498260 cites W2006428370 @default.
• W1991498260 cites W2017778900 @default.
• W1991498260 cites W2024547469 @default.
• W1991498260 cites W2029661050 @default.
• W1991498260 cites W2036975801 @default.
• W1991498260 cites W2041899741 @default.
• W1991498260 cites W2042106885 @default.
• W1991498260 cites W2050928602 @default.
• W1991498260 cites W2054171853 @default.
• W1991498260 cites W2059372582 @default.
• W1991498260 cites W2076278773 @default.
• W1991498260 cites W2076476998 @default.
• W1991498260 cites W2079049265 @default.
• W1991498260 cites W2088070842 @default.
• W1991498260 cites W2102236934 @default.
• W1991498260 cites W2125703217 @default.
• W1991498260 cites W2132083799 @default.
• W1991498260 cites W2138146771 @default.
• W1991498260 cites W2312829609 @default.
• W1991498260 doi "https://doi.org/10.1016/s0140-6736(13)62301-6" @default.
• W1991498260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4255069" @default.
• W1991498260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24485709" @default.
• W1991498260 hasPublicationYear "2014" @default.
• W1991498260 type Work @default.
• W1991498260 sameAs 1991498260 @default.
• W1991498260 citedByCount "347" @default.
• W1991498260 countsByYear W19914982602014 @default.
• W1991498260 countsByYear W19914982602015 @default.
• W1991498260 countsByYear W19914982602016 @default.
• W1991498260 countsByYear W19914982602017 @default.
• W1991498260 countsByYear W19914982602018 @default.
• W1991498260 countsByYear W19914982602019 @default.
• W1991498260 countsByYear W19914982602020 @default.
• W1991498260 countsByYear W19914982602021 @default.
• W1991498260 countsByYear W19914982602022 @default.
• W1991498260 countsByYear W19914982602023 @default.
• W1991498260 crossrefType "journal-article" @default.
• W1991498260 hasAuthorship W1991498260A5005241960 @default.
• W1991498260 hasAuthorship W1991498260A5010334043 @default.
• W1991498260 hasAuthorship W1991498260A5018741279 @default.
• W1991498260 hasAuthorship W1991498260A5018814169 @default.
• W1991498260 hasAuthorship W1991498260A5034582010 @default.
• W1991498260 hasAuthorship W1991498260A5042582706 @default.
• W1991498260 hasAuthorship W1991498260A5051267341 @default.
• W1991498260 hasAuthorship W1991498260A5059565310 @default.
• W1991498260 hasAuthorship W1991498260A5084298635 @default.
• W1991498260 hasAuthorship W1991498260A5091157379 @default.
• W1991498260 hasBestOaLocation W19914982601 @default.
• W1991498260 hasConcept C126322002 @default.
• W1991498260 hasConcept C142724271 @default.
• W1991498260 hasConcept C159110408 @default.
• W1991498260 hasConcept C168563851 @default.
• W1991498260 hasConcept C1862650 @default.
• W1991498260 hasConcept C187212893 @default.
• W1991498260 hasConcept C203014093 @default.
• W1991498260 hasConcept C203092338 @default.
• W1991498260 hasConcept C204787440 @default.
• W1991498260 hasConcept C207480886 @default.
• W1991498260 hasConcept C27081682 @default.
• W1991498260 hasConcept C2776027960 @default.
• W1991498260 hasConcept C2778012357 @default.
• W1991498260 hasConcept C2779951463 @default.
• W1991498260 hasConcept C535046627 @default.
• W1991498260 hasConcept C71924100 @default.
• W1991498260 hasConcept C87813604 @default.
• W1991498260 hasConceptScore W1991498260C126322002 @default.
• W1991498260 hasConceptScore W1991498260C142724271 @default.
• W1991498260 hasConceptScore W1991498260C159110408 @default.
• W1991498260 hasConceptScore W1991498260C168563851 @default.
• W1991498260 hasConceptScore W1991498260C1862650 @default.
• W1991498260 hasConceptScore W1991498260C187212893 @default.
• W1991498260 hasConceptScore W1991498260C203014093 @default.
• W1991498260 hasConceptScore W1991498260C203092338 @default.
• W1991498260 hasConceptScore W1991498260C204787440 @default.
• W1991498260 hasConceptScore W1991498260C207480886 @default.
• W1991498260 hasConceptScore W1991498260C27081682 @default.

• next